Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
DICUMAROL vs HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inhibition of coagulation factors, primarily thrombin (factor IIa) and factor Xa, thereby preventing clot formation and propagation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
Intravenous: Initial bolus of 80 units/kg, followed by continuous infusion at 18 units/kg/hour. Titrate to achieve aPTT of 1.5-2.5 times control or anti-Xa level of 0.3-0.7 units/mL.
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
1-2 hours (dose-dependent); extends to 2.5-4 hours with continuous infusion or renal impairment; clinical context: monitoring via aPTT required
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Category C
Category A/B
Anticoagulant
Anticoagulant